Konakion

Phytomenadione, the active ingredient in Konakion, is a vitamin K drug presented as a sterile solution for intramuscular, intravenous, and oral use. It restores normal blood clotting in patients with vitamin K deficiency, those receiving anticoagulant therapy, and newborns at risk of hemorrhagic disease.

GNH USA supplies Konakion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable logistics and responsive technical support.

Konakion acts on the vitamin K‑dependent coagulation pathway to correct clotting deficiencies.

- Vitamin K deficiency: restores normal clotting factor synthesis in deficient patients. - Anticoagulant‑related bleeding: reverses excessive anticoagulation and reduces bleeding risk. - Neonatal hemorrhagic disease prophylaxis: prevents bleeding in newborns at risk. - Peri‑operative management: reduces bleeding risk during surgery. - Liver disease support: assists clotting factor production in patients with hepatic impairment.

Common Side Effects: - Injection site pain or erythema. - Mild nausea or vomiting. - Transient flushing or warmth. - Headache. - Mild diarrhea. - Skin rash or itching.

Serious or Rare Side Effects: - Anaphylactic reaction. - Severe bleeding despite therapy. - Hemolysis. - Thrombosis or embolic events. - Severe hypersensitivity reactions. - Elevated liver enzymes.

Konakion should be used with caution in specific clinical situations.

- Pregnancy: consult a healthcare professional before use. - Breastfeeding: generally considered compatible, but follow medical advice. - Renal impairment: monitor patient closely. - Concurrent anticoagulant therapy: adjust dose as needed. - Known hypersensitivity: avoid if allergic to phytomenadione. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Konakion may interact with several medications; monitoring is advised.

Major Interactions (Avoid): - Warfarin: may reduce anticoagulant effect, requiring dose adjustment. - Broad‑spectrum antibiotics: can diminish gut vitamin K synthesis, affecting efficacy.

Moderate Interactions (Monitor Closely): - Heparin: additive effect on coagulation, may increase clotting risk. - Other vitamin K supplements: may lead to excess vitamin K activity. - CYP inducers: may alter phytomenadione metabolism, affecting plasma levels.